<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443521</url>
  </required_header>
  <id_info>
    <org_study_id>310/05</org_study_id>
    <nct_id>NCT00443521</nct_id>
  </id_info>
  <brief_title>Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate intravitreal injection of triamcinolone acetonide&#xD;
      after laser panretinal photocoagulation in the treatment of proliferative diabetic&#xD;
      retinopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current gold standard for the treatment of proliferative diabetic retinopathy is&#xD;
      panretinal photocoagulation. Therefore this study is designed using both treatments in the&#xD;
      same patient: intravitreal triamcinolone plus panretinal photocoagulation in one eye,&#xD;
      compared to panretinal photocoagulation alone in the contralateral eye. These patients had&#xD;
      their visual acuity measured and complete ophthalmological examination was performed,&#xD;
      including macular slit lamp examination, fluorescein angiography and optical coherence&#xD;
      tomography.&#xD;
&#xD;
      Patients with symmetric proliferative diabetic retinopathy without high risk characteristics&#xD;
      receive laser therapy in both eyes and triamcinolone injections in one eye. For the&#xD;
      triamcinolone injections, numbing drops, antibiotic drops, and drops to dilate the pupil, and&#xD;
      possibly and anesthetic injection, are put in the eye before the medicine is injected into&#xD;
      the vitreous. Patients return for follow-up visits 1 day, 1 and 4 weeks after the injection,&#xD;
      and then 3 and 6 months. Patients whose condition does not improve may undergo new&#xD;
      evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity (ETDRS)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Optic coherence tomography</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitreous haemorrhage</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerance of the treatment</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide 4 mg intravitreal injection</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Panretinal photocoagulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type II Diabetes&#xD;
&#xD;
          -  symmetric proliferative diabetic retinopathy without high risk characteristics&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous treatment for diabetic retinopathy&#xD;
&#xD;
          -  media opacities that may interfere with clinical, photographically or OCT examinations&#xD;
&#xD;
          -  inability to understands the implications of the protocol&#xD;
&#xD;
          -  Glaucoma or ocular hypertension&#xD;
&#xD;
          -  Any other pathology that could cause retinal alterations&#xD;
&#xD;
          -  Patients with any other situation that may interfere in study completion based in&#xD;
             Investigator´s opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otacílio O Maia Júnior, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina and Vitreous Service, Department of Ophthalmology. Hospital das Clínicas. University of São Paulo School of Medicine, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Y Takahashi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Retina and Vitreous Service, Department of Ophthalmology. Hospital das Clínicas. University of São Paulo School of Medicine, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina and Vitreous Service, Department of Ophthalmology. Hospital das Clínicas. University of São Paulo School of Medicine</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <last_update_submitted>March 2, 2007</last_update_submitted>
  <last_update_submitted_qc>March 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2007</last_update_posted>
  <keyword>Diabetes Mellitus/ complications</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>Laser coagulation</keyword>
  <keyword>Tomography, optical coherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

